Psilocybin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Psilocybin
Accession Number
DB11664
Description

Psilocybin has been investigated for the treatment of Anxiety and Stage IV Melanoma. In November, 2019, it was granted Breakthrough Therapy status by the FDA.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 284.2481
Monoisotopic: 284.092593554
Chemical Formula
C12H17N2O4P
Synonyms
  • Psilocibina
  • Psilocybin
  • Psilocybine
  • Psilocybinum
External IDs
  • CY 39
  • CY-39
  • DEA No. 7437

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Psilocybin.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Psilocybin.
AclidiniumPsilocybin may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Psilocybin.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Psilocybin.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Psilocybin.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Psilocybin.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Psilocybin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Psilocybin.
AlverineThe risk or severity of adverse effects can be increased when Alverine is combined with Psilocybin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Tryptamines and derivatives
Direct Parent
Tryptamines and derivatives
Alternative Parents
Aryl phosphomonoesters / 3-alkylindoles / Alkaloids and derivatives / Aralkylamines / Substituted pyrroles / Benzenoids / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
3-alkylindole / Alkaloid or derivatives / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Aryl phosphate / Aryl phosphomonoester / Azacycle / Benzenoid / Heteroaromatic compound
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organic phosphate, tryptamine alkaloid (CHEBI:8614) / Alkaloids (C07576)

Chemical Identifiers

UNII
2RV7212BP0
CAS number
520-52-5
InChI Key
QVDSEJDULKLHCG-UHFFFAOYSA-N
InChI
InChI=1S/C12H17N2O4P/c1-14(2)7-6-9-8-13-10-4-3-5-11(12(9)10)18-19(15,16)17/h3-5,8,13H,6-7H2,1-2H3,(H2,15,16,17)
IUPAC Name
({3-[2-(dimethylamino)ethyl]-1H-indol-4-yl}oxy)phosphonic acid
SMILES
CN(C)CCC1=CNC2=C1C(OP(O)(O)=O)=CC=C2

References

General References
Not Available
KEGG Compound
C07576
PubChem Compound
10624
PubChem Substance
347828033
ChemSpider
10178
BindingDB
50171269
ChEBI
8614
ChEMBL
CHEMBL194378
ZINC
ZINC000001530830
Wikipedia
Psilocybin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAlcohol Dependence1
2Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)2
2CompletedSupportive CareAnxiety / Depressive Symptomatology / Malignancies1
2Not Yet RecruitingBasic ScienceSevere Depression1
2Not Yet RecruitingTreatmentAlcohol Use Disorder (AUD)1
2Not Yet RecruitingTreatmentMajor depressive disorder, recurrent episode / Treatment Resistant Depression (TRD)2
2RecruitingTreatmentAlcohol Use Disorder (AUD)1
2RecruitingTreatmentCocaine-Related Disorders1
2RecruitingTreatmentMajor Depressive Disorder (MDD)2
2RecruitingTreatmentMajor depressive disorder, recurrent episode / Treatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.7 mg/mLALOGPS
logP1.25ALOGPS
logP-0.14ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)1.74ChemAxon
pKa (Strongest Basic)9.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area85.79 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.3 m3·mol-1ChemAxon
Polarizability27.73 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9010000000-fa35ae02266e8c5497f9
Mass Spectrum (Electron Ionization)MSsplash10-0pb9-9730000000-39c515eadd7ade5cb21a
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 20, 2016 14:38 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates